Dr. Martins on Managing Toxicities Associated With Lenvatinib in DTC

February 25, 2016
Renato G. Martins, MD

Renato G. Martins, MD, medical director of Outpatient General Oncology/Hematology at Seattle Cancer Care Alliance, medical director of Thoracic/Head and Neck Oncology, and professor at the University of Washington School of Medicine, discusses side effects that are associated with lenvatinib (Lenvima).

Renato G. Martins, MD, medical director of Outpatient General Oncology/Hematology at Seattle Cancer Care Alliance, medical director of Thoracic/Head and Neck Oncology, and professor at the University of Washington School of Medicine, discusses side effects that are associated with lenvatinib (Lenvima).

Lenvatinib and sorafenib (Nexavar), both tyrosine kinase inhibitors, are agents used for the treatment of patients with differentiated thyroid cancer (DTC), Martins explains.

While sorafenib may have associated toxicities such as hand-foot syndrome, lenvatinib is associated with mucositis or gastrointestinal events. Martins cautions that these side effects must be proactively managed, citing dose reductions with lenvatinib as a common method.


x